{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:10:05Z","timestamp":1788365405598,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pelvic recurrence of colorectal cancer is a crucial problem because radical surgery can lead to excessive invasion. Novel therapeutic strategies are required instead of surgery. However, there are few suitable models because of the difficulty in transplanting and observing tumors in the pelvis. We have established an appropriate injection site suitable for the establishment of colorectal cancer pelvic recurrence that allows for the observation of tumor growth. DLD-1 cells stably expressing luciferase (DLD-1 clone#1-Luc) were inoculated into various points of female BALB\/c nude mice and the engrafted cells were analyzed with an imaging system employing bioluminescent signals and computed tomography. Weekly analysis with the imaging system showed that a triangular area defined by the vagina, the anus, and the ischial spine was suitable for the engraftment of pelvic tumors. The imaging system was able to detect the engrafted tumor 7 days after the inoculation of cells. Weight loss was observed in our model, and overall survival was 21\u201342 days. Tumor involvement of adjacent organs was detected histopathologically, as is the case in the clinical situation. These findings suggest that this model is valid for evaluations of the therapeutic effects of novel treatments under development. It is hoped that this model will be used in preclinical research.<\/jats:p>","DOI":"10.1038\/s41598-019-56152-0","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T11:03:17Z","timestamp":1577098997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An In Vivo Mouse Model of Pelvic Recurrence of Human Colorectal Cancer"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-479X","authenticated-orcid":false,"given":"Masashi","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Masubuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomo","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taka-Aki","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"56152_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin. 65, 87\u2013108 (2015).","journal-title":"CA Cancer J Clin."},{"key":"56152_CR2","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/S0140-6736(86)91510-2","volume":"1","author":"RJ Heald","year":"1986","unstructured":"Heald, R. J. & Ryall, R. D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1, 1479\u20131482 (1986).","journal-title":"Lancet."},{"key":"56152_CR3","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.ejca.2008.05.004","volume":"44","author":"M Den Dulk","year":"2008","unstructured":"Den Dulk, M. et al. Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-oeprative radiotherapy. Eur J Cancer. 44, 1710\u20131716 (2008).","journal-title":"Eur J Cancer."},{"key":"56152_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.surg.2008.09.014","volume":"145","author":"S Ishiguro","year":"2009","unstructured":"Ishiguro, S. et al. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery. 145, 189\u2013195 (2009).","journal-title":"Surgery."},{"key":"56152_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/mco.2016.1098","volume":"6","author":"K Kondo","year":"2017","unstructured":"Kondo, K. et al. Clinical implications of preoperative chemoradiotherapy prior to laparoscopic surgery for locally advanced low rectal cancer. Molec Clin Oncol. 6, 23\u201328 (2017).","journal-title":"Molec Clin Oncol."},{"key":"56152_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000002212","volume":"266","author":"S Fujita","year":"2017","unstructured":"Fujita, S. et al. Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II\/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 266, 201\u2013207 (2017).","journal-title":"Ann Surg."},{"key":"56152_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1463-1318.2012.03005.x","volume":"14","author":"A Bhangu","year":"2012","unstructured":"Bhangu, A., Ali, S. M., Darzi, A., Brown, G. & Tekkis, P. Meta-Analysis of survival based on resection margin status following surgery for recurrent rectal cancer. Colorectal Dis. 14, 1457\u20131466 (2012).","journal-title":"Colorectal Dis."},{"key":"56152_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00000658-199410000-00017","volume":"220","author":"HJ Wanebo","year":"1994","unstructured":"Wanebo, H. J., Koness, R. J., Vezeridis, M. P., Cohen, S. I. & Wrobleski, D. E. Pelvic resection of recurrent rectal cancer. Ann Surg. 220, 586\u2013595 (1994).","journal-title":"Ann Surg."},{"key":"56152_CR9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/cncr.10799","volume":"95","author":"M Mohiuddin","year":"2002","unstructured":"Mohiuddin, M., Marks, G. & Marks, J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer. 95, 1144\u20131150 (2002).","journal-title":"Cancer."},{"key":"56152_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/DCR.0000000000000015","volume":"57","author":"DT Colibaseanu","year":"2014","unstructured":"Colibaseanu, D. T. et al. Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes? Dis Colon Rectum. 57, 47\u201355 (2014).","journal-title":"Dis Colon Rectum."},{"key":"56152_CR11","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1245\/s10434-014-4317-y","volume":"22","author":"M Neilsen","year":"2015","unstructured":"Neilsen, M. et al. Early and late outcomes of surgery for locally recurrent rectal cancer: a prospective 10-year study in the total mesorectal excision era. Ann Surg Oncol. 22, 2677\u20132684 (2015).","journal-title":"Ann Surg Oncol."},{"key":"56152_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2016.04.022","volume":"96","author":"S Yamada","year":"2016","unstructured":"Yamada, S. et al. Working Group on Locally Recurrent Rectal Cancer. Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys. 96, 93\u2013101 (2016).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"56152_CR13","doi-asserted-by":"publisher","first-page":"9266","DOI":"10.1073\/pnas.0702427104","volume":"104","author":"Q le Masne de Chermont","year":"2007","unstructured":"le Masne de Chermont, Q. et al. Nanoprobes with near-infrared persistent luminescence for in vivo imaging. Proc Natl Acad Sci USA 104, 9266\u20139271 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"56152_CR14","first-page":"4389","volume":"29","author":"MA Shibata","year":"2009","unstructured":"Shibata, M. A. et al. An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging. Anticancer Res. 29, 4389\u20134395 (2009).","journal-title":"Anticancer Res."},{"key":"56152_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3346\/jkms.2011.26.11.1439","volume":"26","author":"JE Hwang","year":"2011","unstructured":"Hwang, J. E. et al. Intravenous KITENIN shRNA injection suppresses hepatic metastasis and recurrence of colon cancer in an orthotopic mouse model. J Korean Med Sci. 26, 1439\u20131445 (2011).","journal-title":"J Korean Med Sci."},{"key":"56152_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/thy.2013.0149","volume":"24","author":"L Zhang","year":"2014","unstructured":"Zhang, L. et al. An in vivo mouse model of metastatic human thyroid cancer. Thyroid. 24, 695\u2013704 (2014).","journal-title":"Thyroid."},{"key":"56152_CR17","first-page":"5179","volume":"16","author":"HY Feng","year":"2018","unstructured":"Feng, H. Y. et al. Characterization of an orthotopic gastric cancer mousemodel with lymph node and organ metastases using bioluminescence imaging. Oncol Lett. 16, 5179\u20135185 (2018).","journal-title":"Oncol Lett."},{"key":"56152_CR18","doi-asserted-by":"publisher","first-page":"2920384","DOI":"10.1155\/2017\/2920384","volume":"2017","author":"L Jia","year":"2017","unstructured":"Jia, L. et al. Effect of combined simultaneous and sequential endostar and cisplatin treatment in a mice model of gastric cancer peritoneal metastases. Gastroenterol Res Pract. 2017, 2920384, https:\/\/doi.org\/10.1155\/2017\/2920384 (2017).","journal-title":"Gastroenterol Res Pract."},{"key":"56152_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/tox.22581","volume":"33","author":"YS Ma","year":"2018","unstructured":"Ma, Y. S. et al. Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. Environ Toxicol. 33, 1097\u20131104 (2018).","journal-title":"Environ Toxicol."},{"key":"56152_CR20","first-page":"812","volume":"57","author":"WF Dove","year":"1997","unstructured":"Dove, W. F. et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57, 812\u2013814 (1997).","journal-title":"Cancer Res."},{"key":"56152_CR21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/DCR.0000000000001096","volume":"61","author":"N Hite","year":"2018","unstructured":"Hite, N. et al. An optimal orthotopic mouse model for human colorectal cancer primary tumor growth and spontaneous metastasis. Dis Colon Rectum. 61, 698\u2013705 (2018).","journal-title":"Dis Colon Rectum."},{"key":"56152_CR22","doi-asserted-by":"publisher","first-page":"e0136981","DOI":"10.1371\/jounal.pone.0136981","volume":"10","author":"K Takahara","year":"2015","unstructured":"Takahara, K. et al. The anti-proliferative effect of born neutron capture therapy in a prostate cancer xenograft model. PLoS One. 10, e0136981, https:\/\/doi.org\/10.1371\/jounal.pone.0136981 (2015).","journal-title":"PLoS One."},{"key":"56152_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2015.03.026","volume":"363","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi, K. et al. MicroRNA-124 inhibits cancer cell growth through PTB1\/PKM1\/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 363, 17\u201327 (2015).","journal-title":"Cancer Lett."},{"key":"56152_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.omtm.2019.02.005","volume":"13","author":"Y Yoshikawa","year":"2019","unstructured":"Yoshikawa, Y. et al. Anti-cancer effects of a chemically modified miR-143 on bladder cancer by either systemic or intervesical treetment. Mol Ther Methods Clin Dev. 13, 290\u2013302 (2019).","journal-title":"Mol Ther Methods Clin Dev."},{"key":"56152_CR25","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.bmcl.2019.05.044","volume":"29","author":"SI Wada","year":"2019","unstructured":"Wada, S. I. et al. Influence of lysine residue in amphipathic helical peptide on targeted delivery of RNA into cancer cells. Bioorg Med Chem Lett. 29, 1934\u20131937 (2019).","journal-title":"Bioorg Med Chem Lett."},{"key":"56152_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. & Altman, D. G. NC3Rs Reporting Guidelines Working Group. Animal Research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 160, 1544\u20131579 (2010).","journal-title":"Br J Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56152-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:47:50Z","timestamp":1671299270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56152"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56152-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19630"}}